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Abstract
Background: The urokinase-type (uPA) and tissue-type (tPA) plasminogen activators regulate
liver matrix remodelling through the conversion of plasminogen (Plg) to the active protease
plasmin. Based on the efficient activation of plasminogen when uPA is bound to its receptor (uPAR)
and on the role of uPA in plasmin-mediated liver repair, we hypothesized that uPA requires uPAR
for efficient liver repair.
Methods: To test this hypothesis, we administered one dose of carbon tetrachloride (CCl4) to
mice with single or combined d e f i c i e n c i e s  o f  u P A ,  u P A R  and tPA, and examined hepatic
morphology, cellular proliferation, fibrin clearance, and hepatic proteolysis 2–14 days later.
Results: Absence of uPAR alone or the combined absence of uPAR and tPA had no impact on the
resolution of centrilobular injury, but the loss of receptor-free uPA significantly impaired the
clearance of necrotic hepatocytes up to 14 days after CCl4. In response to the injury, hepatocyte
proliferation was normal in mice of all genotypes, except for uPAR-deficient (uPAR°) mice, which
had a reproducible but mild decrease by 33% at day 2, with an appropriate restoration of liver mass
by 7 days similar to experimental controls. Immunostaining and zymographic analysis demonstrated
that uPA alone promoted fibrin clearance from centrilobular regions and efficiently activated
plasminogen.
Conclusion: uPA activates plasminogen and promotes liver matrix proteolysis during repair via a
process that neither requires its receptor uPAR nor requires a contribution from its functional
counterpart tPA.
Background
Tissue repair and remodelling in response to injury
require well-coordinated cellular proliferation in syn-
chrony with reorganization of the extracellular matrix.
After a toxic injury resulting in focal hepatic necrosis, liver
cells undergo proliferation events to recover the original
hepatic mass in a time-restricted fashion [1-3]. This prolif-
erative response must be matched by the proteolytic clear-
ance of necrotic cells and matrix reorganization to restore
the lobular architecture [4-6]. While the proliferative
response is regulated by the expression of cytokines,
growth factors and transcription factors [7-9], debris clear-
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ance and extracellular matrix remodelling are driven in
part by tissue-derived and circulating proteases. Based on
the observation that liver repair is severely compromised
in mice lacking plasminogen (Plg), the Plg family of pro-
teases emerged as key mediators of matrix proteolysis/
remodelling following an injury. The hepatic proliferative
response is not impeded in Plg-deficient mice following a
single administration of hepatotoxin, but the clearance of
necrotic foci and the restoration of normal lobular organ-
ization are severely impaired within the liver of Plg-defi-
cient mice relative to control animals [6,10,11].
In order to exhibit proteolytic activity with macromolecu-
lar substrates, Plg must be proteolytically converted to the
two-chain serine protease plasmin by urokinase-type
(uPA) or tissue-type (tPA) plasminogen activator. uPA has
been proposed to play an important role in liver regener-
ation based on a decrease in the proliferative response of
hepatocytes following partial hepatectomy [12]. However
in the model of liver repair due to toxic insult, we found
that loss of uPA did not result in decreased proliferation
of hepatocytes [13]. The reason for this discrepancy in the
role of uPA regulating hepatocyte proliferation may be
due to differences in molecular pathways regulating the
hepatic response to a physical injury (as in partial hepate-
ctomy) and a toxic insult (CCl4 injury), as well as injuries
induced by other experimental models such as the admin-
istration of anti-Jo2 antibody [14]. In this experimental
context, the loss of uPA resulted in a moderate defect in
liver repair despite normal hepatic proliferation and the
combined loss of uPA and tPA led to a more profound
defect in liver repair akin to the findings in Plg-deficient
mice [13]. Exuberant transgene-mediated hepatic expres-
sion of uPA failed to correct the reparative defect observed
within the liver of Plg-deficient mice [15], suggesting that
plasmin(ogen) is central to hepatic remodelling after
acute toxic injury. However, it remains to be determined
whether binding of uPA to its receptor (uPAR) on the sur-
face of either hepatocytes or other cells is important for
liver repair by localizing Plg activation to the immediate
pericellular microenvironment.
Binding of uPA to its cellular receptor uPAR is important
for the efficient activation of plasminogen at the cellular
surface in several in vivo and in vitro systems [16-21]. In
addition to supporting pericellular zymogen activation,
the formation of the uPA-uPAR complex on the cell sur-
face is known to influence cell adhesion, migration, and
chemotactic properties [17-20,22]. Based on these find-
ings, we hypothesized that binding of uPA to uPAR is
required for efficient liver repair. To address this question,
we investigated the hepatic reparative response in mice
with single or combined deficiencies in uPA, uPAR and
tPA. We report that uPA-mediated plasminogen activation
is important for the timely repair of the hepatic tissue fol-
lowing an acute injury, but efficient liver repair can be
achieved in the absence of uPAR and in the absence of any
benefit of tPA-mediated plasminogen activation.
Methods
Gene-targeted mice
Mice with individual disruption of the genes encoding
uPA (uPA°), uPAR (uPAR°), and tPA (tPA°) were of
mixed genetic background 129/C57BL/6, and were geno-
typed by PCR using tail DNA and specific primers as
described previously [13,23]. Mice with the combined
loss of uPAR and tPA (uPAR°/tPA°) were also included in
the experimental design to generate a biological system
displaying soluble uPA as the only means to activate Plg
[23,24] ; non-targeted wild-type (WT) littermates served
as controls. All the experimental challenges were per-
formed in 2- to 6-month old littermates housed in stand-
ard facilities and fed food and water ad libitum. Animal
protocols were approved by the Institutional Animal Care
and Use Committee of the Cincinnati Children's Research
Foundation (Cincinnati, OH, USA).
Liver injury
Gene-targeted mice and control littermates were chal-
lenged with a single intraperitoneal injection of CCl4
(Aldrich Chemical Inc., Milwaukee, WI) at a dose of 12.5
μl CCl4 per 25-gram body weight delivered in a 25% solu-
tion in corn oil. Mice were examined daily and sacrificed
at days 2, 7, and 14 after CCl4 as described previously
[6,11]. In brief, the mice were weighed, sacrificed, and
blood was collected from the inferior vena cava at the time
of sacrifice. Livers were excised, embedded in paraffin, sec-
tioned, and stained with hematoxylin and eosin for histo-
logical analysis. Biochemical markers of liver function
and injury were determined in plasma by automated
enzymatic assay using Vistros Chemistry Systems 950
(Johnson and Johnson, Rochester, NY) [25].
Zymography to determine Plg activation
Liver protein lysates were isolated by homogenization in
solubilization buffer containing 1% Nonidet-P40, 0.5%
deoxycholate, 0.1% Sodium Dodecyl Sulfate, and 10%
Protease inhibitor cocktail (Sigma Chemical Co., St.
Louis, MO) as described previously [13]. After homogeni-
zation, the soluble fraction was collected from the super-
natant by centrifugation at 12,000 g for 15 min. Protein
concentration was determined using the Bradford method
based Bio-Rad assay (Bio-Rad Laboratory Inc., Hercules,
CA). For zymography, 50 μg of total protein was assayed
using 12.5% polyacrylamide gel cast containing 0.4%
nonfat dry milk and 20 μg/ml Plg, as described previously
[13]. Briefly, gels were washed twice for 30 min in 2.5%
Triton X-100 after electrophoresis and then incubated for
16 hr at 37°C in 0.1 M glycine (pH 8.0). Caesinolytic
areas were determined by Coomasie blue staining.BMC Gastroenterology 2006, 6:40 http://www.biomedcentral.com/1471-230X/6/40
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Fibrinogen staining
To investigate the deposition of fibrin(ogen) in the
hepatic lobule, immunohistochemistry was performed on
liver sections using a rabbit anti-fibrin(ogen) antiserum
followed by detection with the Vectastain ABC-AP stain-
ing system (Vector Laboratories, Burlingame, CA) and
Fast Red TR/naphthol AS-MX (Sigma Chemicals, St. Louis,
MO) as described previously [11].
Hepatocyte proliferation
The proliferative response of hepatocytes after CCl4 injec-
tion was measured by incorporation of bromodeoxyurid-
ine (BrdU), which was administered intraperitoneally to
all mice 2 hr before sacrifice as described previously [25].
BrdU-labelled hepatocytes were identified on 4 μm sec-
tions of paraffin-embedded liver samples according to
manufacturer's instructions (Cell proliferation kit, Amer-
sham Life Science, Arlington Heights, IL) as described pre-
viously [13]. For each sample, the hepatocyte-labelling
index (percent of hepatocytes incorporating BrdU) was
calculated by counting BrdU-labelled and unlabeled
hepatocyte nuclei in 10 high-power fields (~100 hepato-
cyte nuclei/field) by an investigator unaware of the ani-
mal genotype. Hepatocyte proliferation was expressed as
the mean +/- standard deviation (SD) for all mice in each
group (n = 3–6 mice/group).
Purification of hepatocyte growth factor
Cytosolic hepatocyte growth factor (HGF) was partially
purified from livers as described previously [26]. Briefly,
livers were homogenized in 4 volumes of ice-cold lysis
buffer {50 mM Tris-HCl (8.5), 0.15 M NaCl, 10 mM
EDTA, 100 μM Nafamostat mesilate and 1 mM PMSF},
followed by removal of cellular debris by centrifugation at
25,000 g for 20 min and 105,000 g for 60 min at 4°C.
Supernatant containing soluble proteins was supple-
mented with 0.1% CHAPS and passed through S-Sepha-
rose column. Eluate was concentrated by ultrafiltration
using Centricon 30 (Amicon) following the manufac-
turer's instructions, electrophoresed on 10% SDS-PAGE
under reducing conditions, transferred to nitrocellulose
membrane, incubated with goat anti-mouse HGF anti-
body (Santa Cruz Biotechnology Inc, Santa Cruz, CA), AP-
conjugated rabbit anti-goat antibody (Vector Laborato-
ries, Burlingame, CA), and the specific signals of single
and heavy chains were detected with enhanced chemilu-
minescence (Amersham Biosciences, Piscataway, NJ).
Quantification of CD11b cells in the regenerating liver
To isolate hepatic mononuclear cells, peripheral blood
was flushed out from the liver by infusion of PBS through
the portal vein, followed by excision and mincing of the
liver, passing the cell suspension through 40 μm nylon
strainer (BD Biosciences, Franklin Lakes, NJ, USA) in
RPMI Medium 1640 supplemented with 4% fetal calf
serum (Life Technologies Inc., Grand Island, NY, USA)
and centrifugation at 75 g for 2 min to remove cellular
debris as described previously [27]. The cell suspension
was treated with red blood cell lysis buffer (0.15 M
NH4Cl, 10 mM KHCO3, and 0.1 mM Na2EDTA at pH
7.2), centrifuged at 270 g for 10 min, resuspended in PBS
containing 4% fetal calf serum, and labelled with anti-
mouse Fc II/III receptor mAb (to block non-specific bind-
ing) and FITC-conjugated anti-mouse CD11b mAbs (BD
Biosciences, San Jose, California, USA), and analyzed in a
FACSCalibur dual-laser flow cytometer as described previ-
ously [27,28].
Statistical analysis
Statistical analysis was performed with one-way ANOVA
to assess for intergroup and intragroup differences and by
unpaired student's t-test for two-group comparisons, with
a significance level set at P < 0.05.
Results
Outcome of liver repair in uPAR° mice
A single dose of the hepatotoxin CCl4 results in an acute
necroinflammatory injury to centrilobular hepatocytes
due to the conversion of CCl4 to the free radical CCl3 and
other highly reactive species [6,29]. To explore the role of
uPAR in uPA-mediated plasminogen activation during
liver repair, mice were challenged with a single dose of
CCl4. In keeping with the development of an acute hepa-
tocellular injury, serum levels of alanine aminotransferase
(ALT) increased at 2 days and returned to baseline levels
by 7 days, regardless of the availability of uPAR or plas-
minogen activator (Figure 1). Interestingly, uPA° mice
displayed low baseline levels of ALT when compared to
mice of other genotypes (P = 0.023), but all baseline levels
were within normal limits. While the reason for the low
baseline level in uPA° mice is not known, ALT levels
increased to similar levels of WT mice at the time of acute
injury (2 days). Therefore, deficiency of uPA/uPAR did not
affect the initial degree of liver damage or the transient
hepatotoxicity induced by CCl4 as indicated by ALT levels.
Consistent with the rise in serum ALT, visual inspection of
livers 2 days after CCl4 revealed a similar diffuse pale lacy
appearance in all mice regardless of genotype (data not
shown). The gross appearance of livers of wild type,
uPAR° and uPAR°/tPA° mice normalized within 7 days
of CCl4 administration. This normal appearance of livers
from uPAR°/tPA° mice was the first indication that recep-
tor-free uPA was sufficient for the reparative response. In
contrast, livers of mice with the single loss of uPA contin-
ued to display a pale lacy appearance at 7 days, with slight
improvement at 14 days after CCl4.
To investigate the microscopic basis for the abnormal vis-
ual appearance after CCl4, we performed histological
analysis of paraffin-embedded liver sections of uPAR°BMC Gastroenterology 2006, 6:40 http://www.biomedcentral.com/1471-230X/6/40
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mice and experimental controls after CCl4. Two days after
injury, all livers exhibited widespread liquefaction necro-
sis in centrilobular hepatocytes regardless of the genotype,
with minimal inflammation and intact cellular compo-
nents in the remainder of the liver lobule (Figure 2). Sys-
tematic analysis of liver sections at 7 and 14 days
following CCl4 showed that the centrilobular injury of
uPAR° mice resolved completely by 7 days in a fashion
similar to the resolution observed in wild type and
uPAR°/tPA° mice (Figure 2). This was in stark contrast to
the persistent centrilobular injury in livers of uPA° mice
that persisted through 14 days. The persistence of the cen-
trilobular injury in the setting of normalization in the lev-
els of ALT is consistent with a defect in repair, rather than
ongoing injury, as described previously [13].
Collectively, these data indicate that the presence of uPA
is critical for the efficient resolution of the centrilobular
injury; but the loss of uPAR does not appreciably hinder
the ability of receptor-free uPA to orchestrate the repara-
tive response of the liver to CCl4.
Lack of uPAR results in a mild, transient decrease in 
hepatocyte proliferation
Based on the pleiotropic role of uPAR as a regulator of cell
proliferation, pericellular proteolysis, and cellular differ-
entiation [30,31], we investigated whether the loss of
uPAR impairs hepatocyte proliferation after CCl4 admin-
istration. Using BrdU incorporation by hepatocytes as an
indicator of proliferation, we found that hepatocyte pro-
liferation increased substantially in all mice regardless of
the genotype 2 days after CCl4. Interestingly, the prolifer-
ative index was mildly lower in livers of uPAR° mice (one-
way ANOVA, P < 0.002), 33.3% below the index in livers
from WT mice (Student's t test, P < 0.004; Figure 3). While
statistically significant and reproducible in two independ-
ent experiments, this difference was modest and did not
modify the return to baseline levels of hepatocyte prolif-
eration by 7–14 days. The transient decrease in prolifera-
tion did not influence the restoration of the lobular
architecture; the persistent centrilobular injury was
present only in uPA° mice. Since HGF is a potent mitogen
to hepatocytes [32], we reasoned that the transient
decrease in hepatocyte proliferation could be due to
decreased activation of HGF. To examine this possibility,
we used western analysis and found no difference in the
expression levels of single-chain or activated forms of
cytosolic HGF in uPAR° mice either before CCl4 adminis-
tration or at day 2 following CCl4 when compared to WT
mice (Figure 4). Because uPAR plays an important role in
regulating the migration of macrophages and modulating
the expression of cytokines [33-39], we determined the
total number of hepatic CD11b-labeled cells in WT and
uPAR° mice by flow cytometry 2 days after injury. We
found no difference in the number of CD11b-labeled cells
(2.4 × 106/livers in WT mice versus 2.2 × 106/livers in
uPAR° mice, P = 0.8294, n = 3 for each group). Com-
bined, these data suggest that the transient decrease in
hepatocyte proliferation in uPAR° mice is not due to
changes in HGF activation or migration of immune cells
in these livers. Notably, hepatocyte proliferation did not
differ between uPA° and WT mice, but the liver to body
weight ratio in uPA° mice showed a clear trend to increase
over time (Figure 5); this was similar to the findings pre-
viously described in Plg-deficient mice due to the accumu-
lation of fibrin in injured areas [6,13]. Therefore, we next
determined whether fibrin clearance is impaired in uPAR°
mice.
Loss of uPAR does not lead to impaired clearance of the 
provisional fibrin in diseased livers
We investigated whether clearance of fibrin in the hepatic
lobule is impaired in uPA°, uPAR° and uPAR°/tPA° mice
after CCl4. Immunohistochemical analysis of the liver sec-
tions 2 days after CCl4 showed that fibrin deposition in
injured centrilobular regions was a prominent feature
throughout the liver lobules in mice of all genotypes (Fig-
ure 6). However, this centrilobular fibrin deposition was
transient in livers of uPAR° and uPAR°/tPA° mice, which
allowed for timely fibrin removal by 7 days similar to WT
mice. In mice lacking uPA, fibrin deposition was still evi-
dent at 14 days after CCl4 administration. These findings
imply that uPA promotes the proteolytic clearance of
fibrin-rich matrix independent of its high affinity receptor
and independent of tPA.
Levels of serum alanine aminotransferase (ALT) after CCl4 Figure 1
Levels of serum alanine aminotransferase (ALT) 
after CCl 4 . Serum levels of ALT peak 2 days following 
CCl4 administration in mice of all genotypes. Thereafter, the 
values return to basal levels within 7 to 14 days in a similar 
manner in all experimental groups (n = 3–8 at each time 
point). * P = 0.023 when compared experimental controls.BMC Gastroenterology 2006, 6:40 http://www.biomedcentral.com/1471-230X/6/40
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Total hepatic uPA is similar with and without uPAR
Binding of uPA to uPAR has been shown to increase pro-
teolytic activation in vitro [40]. Thus, to explore whether
loss of uPAR alters the level of hepatic uPA, we deter-
mined the ability of liver protein extracts to activate Plg.
Using zymographic analysis, we found that total liver pro-
tein induced activation of Plg at the predicted molecular
weight for uPA in hepatic extracts from all genotypes
except for livers of uPA° mice (Figure 7). This was evident
2 days after CCl4, a time point with similar levels of uPA
in wild type, uPAR° and uPAR°/tPA° mice as well as at
later time points (7 and 14 days). These results support
the hypothesis that the loss of hepatic uPAR does not alter
the ability of uPA to induce Plg activation during the
reparative response of the liver to an acute injury.
Discussion
Our data show that among the effectors of plasminogen
activation (uPA, tPA and uPAR), uPA alone is able to effi-
ciently promote liver repair. It can do so independently
from its receptor and without any added contribution
from its functional counterpart, tPA. This was evidenced
by the findings that the loss of uPAR did not affect the ini-
Impaired resolution of centrilobular injury in mice lacking receptor-free uPA Figure 2
Impaired resolution of centrilobular injury in mice lacking receptor-free uPA. Histological liver sections 2 days after 
CCl4 show similar features of centrilobular necrosis (arrows) in mice of all genotypes. While livers from wild type (WT), 
uPAR°, and uPAR°/tPA° show resolution of the centrilobular injury by day 7, uPA° livers continue to display the injury at 7 and 
14 days after CCl4 despite the presence of uPAR (Magnification 200×)
Transient decrease in proliferation of hepatocytes in mice  lacking uPAR Figure 3
Transient decrease in proliferation of hepatocytes in 
mice lacking uPAR. Quantification of BrdU-labeled hepa-
tocytes shows a rise in BrdU uptake in all experimental 
groups 2 days after CCl4, with a decrease of ~33% in uPAR° 
livers. The percent of BrdU-labeled hepatocytes return to 
near baseline levels in all groups. WT = wild type. (*ANOVA 
P < 0.004; @t-test P < 0.004; N = 3–8 at each time point).BMC Gastroenterology 2006, 6:40 http://www.biomedcentral.com/1471-230X/6/40
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tial degree or features of the centrilobular injury induced
by CCl4, or the time required for the liver to restore the
normal lobular architecture. Interestingly, there was a
mild, transient attenuation in the proliferative response in
the absence of uPAR, which did not impact the return to
baseline levels of proliferation or restoration of liver mass.
Furthermore, the timely clearance of the provisional fibrin
matrix in injured centrilobular regions and the levels of
uPA in both uPAR° and uPAR°/tPA° livers underscore the
non-essential contribution of uPAR and tPA in the liver-
specific plasminogen activation/fibrinolysis during liver
repair. Collectively, these data demonstrate that while
binding of uPA to its receptor may optimize liver cell pro-
liferation and repair, the primary functions of fibrin
removal, clearance of necrotic cells, and reorganization of
the liver lobule can be efficiently accomplished solely
with receptor-free uPA. It is conceivable, if not likely, that
both plasminogen activation and plasmin-mediated pro-
teolysis within damaged liver tissue may be less efficient
in the absence of uPAR-supported uPA localization. How-
ever, if so, then the current data indicate that the residual
plasminogen activation and plasmin-mediated proteoly-
sis in uPAR-deficient mice is adequate to support fibrin
clearance and hepatic repair that is comparable to wild-
type mice. The normal liver repair mediated by uPA in the
absence of both tPA and uPAR might argue the case for the
existence of undefined compensatory networks or of other
receptors for uPA that facilitate plasminogen activation;
these molecules, however, are largely undefined. It might
also argue for the more likely scenario in which soluble
uPA is able to efficiently activate plasminogen and facili-
tate plasmin-mediated liver repair.
The decrease in liver cell proliferation after an acute toxic
injury in uPAR° mice is in keeping with the role of uPAR
in promoting cellular proliferation, proteolysis and cellu-
lar differentiation in extra-hepatic systems [30,31]. A
decrease in hepatocyte proliferation has also been
reported following 70% partial hepatectomy in uPA°
mice [12]. In these studies, livers of uPA° mice also accu-
mulated fibrin within the lobule of regenerating liver.
However, these findings were transient and did not impair
the timely restoration of the liver mass or modify the long-
term survival of the organism. It is possible that a deficit
in the generation of plasmin in the hepatic environment
of uPAR° mice may be responsible for the transient
depression in hepatocyte proliferation after CCl4 based on
the role of uPAR and uPA in plasminogen activation
[17,41,42]. However, this seems unlikely in view of the
normal proliferative response observed in plasminogen-
deficient mice following CCl4 injury [6]. Alternatively, the
decreased proliferation may be due to impaired activation
of growth-related signals in uPAR° livers. This scenario is
supported by the role of the ligand uPA in the proteolytic
activation of the potent liver cell mitogen hepatocyte
growth factor (HGF) into its active heterodimeric form
[43,44], and by the recent findings that uPAR is one of the
downstream targets of the HGF receptor cMet tyrosine
kinase in the KM12L4 human epithelial cell line [45].
However our data did not show significant changes in the
activation of cell-associated HGF during early phases of
the regenerative response after CCl4. We also found no
influence of uPAR in the ability of macrophages to popu-
Normal activation of cell-associated hepatocyte growth fac- tor in uPAR° livers during liver repair Figure 4
Normal activation of cell-associated hepatocyte 
growth factor in uPAR° livers during liver repair. 
Western analysis of hepatocyte growth factor (HGF) partially 
purified from the soluble fraction of liver extracts using an 
antibody that recognizes the single chain and heavy chain (to 
demonstrate activation) of HGF shows similar levels of acti-
vation in WT and uPAR° livers at baseline (day 0) or at 2 
days after CCl4 administration. scHGF = single chain HGF; 
aHGF = activated HGF, rHGF = recombinant HGF.
Maintenance of liver mass following CCl4 Figure 5
Maintenance of liver mass following CCl 4 . Analysis of 
the liver mass (expressed as the wet liver weight as a per-
centage of the body weight) shows a mild increase in all gen-
otypes 2 days after CCl4 administration, followed by a trend 
toward baseline levels by 14 days, except for livers of uPA° 
mice which continue to display a mass that is similar to day 2 
(and higher than before CCl4, *P < 0.03). WT = wild type.BMC Gastroenterology 2006, 6:40 http://www.biomedcentral.com/1471-230X/6/40
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late the liver after the toxic injury. Regardless of the mech-
anism(s) downregulating the proliferative response, the
impact of uPAR loss on hepatocyte proliferation was over-
shadowed by a more prominent defect in the proteolytic
clearance of necrotic cells and in lobular reorganization in
mice lacking uPA.
The normal liver repair in mice with the combined loss of
uPAR and tPA clearly demonstrates that the presence of
uPA alone (i.e., not receptor bound and without tPA-
dependent activation of plasminogen) is able to restore
the lobular architecture in a timely fashion. Based on the
established requirement of plasminogen to implement
effective liver repair, plasmin-mediated extracellular pro-
teolysis is likely to couple receptor-free uPA to hepatic
repair. Fibrin appears to be one target of plasmin in this
context, but it should be noted that studies of fibrinogen-
deficient mice indicate that fibrin(ogen) is not the only
plasmin substrate relevant to hepatic repair [6]. Taken
together, the available data suggest that soluble uPA sup-
ports hepatic repair and this appears to be achieved
through a mechanism linked to plasmin-mediated prote-
olysis of fibrin and non-fibrin substrates at sites of injury.
Receptor-free uPA is required for fibrin clearance Figure 6
Receptor-free uPA is required for fibrin clearance. Detection of fibrin deposition by immunohistochemistry (red stain, 
arrows) shows uniform staining in centrilobular area in livers of mice of all genotypes 2 days after CCl4. The clearance of fibrin 
coincides with the resolution of the centrilobular injury by day 14 in mice of each genotype, except for uPA° mice. (Magnifica-
tion 200×)
Hepatic uPA activation occurs in the absence of uPAR Figure 7
Hepatic uPA activation occurs in the absence of uPAR. 
Activation of uPA in the liver was observed in mice of all geno-
types after CCl4, except in uPA° mice. The upper band (arrow) 
depicts tPA while the lower band (arrow head) depicts uPA.BMC Gastroenterology 2006, 6:40 http://www.biomedcentral.com/1471-230X/6/40
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Conclusion
While binding of uPA to uPAR amplifies the properties of
uPA in extra-hepatic systems, loss of uPAR did not signif-
icantly impair plasminogen activation or liver repair. The
presence of its ligand uPA alone can promote plasmino-
gen activation at levels that are sufficient to support liver
repair after an acute injury.
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